• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

pneeson@unimelb.edu.au

Credentials


Position
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
Education
Bachelors Degree
RMIT University
ORCID

0000-0002-2729-5887

Prof Paul Neeson

Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology

223 Scholarly works
13 Projects

HIGHLIGHTS

  • 2026

    Journal article

    [177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study
    DOI: 10.1016/S1470-2045(26)00017-3
  • 2026

    Journal article

    P0350 Biochemical recurrence and safety in patients with high-risk localised prostate cancer treated with [177Lu] Lu-PSMA-617 prior to prostatectomy: Follow-up of the LuTectomy trial
    DOI: 10.1016/s0302-2838(26)01246-7
  • 2026

    Journal article

    Metastasis-directed therapy with or without pembrolizumab for oligometastatic clear cell renal cell carcinoma: Pooled analysis of two prospective single-arm phase II trials.
    DOI: 10.1200/jco.2026.44.7_suppl.498
  • 2026

    Journal article

    Parity and lactation induce T-cell-mediated breast cancer protection
    DOI: 10.1038/s41586-025-09713-5
  • 2021

    Research grants (international)

    Identifying Genetic, Transcriptional and Microenvironment Drivers of Lethal Prostate Cancer for Better Patient Stratification, Disease Tracking and Drug Target Discovery
  • 2017

    Research grants (other domestic)

    Novel Approaches for Overcoming Resistance to Therapies for Advanced Melanoma
  • 2017

    Research Grant

    Combination of Radionuclide 177lu-Psma Therapy With Pembrolizumab in Patients With Metastatic Castration-Resistant Prostate Cancer (Mcrpc)
Paul Neeson

RECENT SCHOLARLY WORKS

  • 2026

    Journal article

    Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials
    DOI: 10.1016/j.eururo.2026.03.024
  • 2026

    Journal article

    Bispecific antibody combination therapies in diffuse large B-cell lymphoma
    DOI: 10.1111/bjh.70228
  • 2025

    Conference Proceedings

    Development of a novel CAR-T cell therapy using a multimodal approach to target T cell lymphoma
    DOI: 10.1182/blood-2025-4112
  • 2025

    Conference Proceedings

    DLBCL tumor microenvironment archetype and CD4 T cell conversion to cytotoxic cells are required for response to glofitamab
    DOI: 10.1182/blood-2025-557
  • 2025

    Conference Proceedings

    Integrative analysis of the tumour immune microenvironment of breast implant-associated anaplastic large cell lymphoma using multi-omics
    DOI: 10.1182/blood-2025-3563
  • 2025

    Journal article

    Personalized Immunotherapy for T Cell Lymphomas: From Immune Escape to Precision Therapeutics
    DOI: 10.3390/jpm15110560

RECENT PROJECTS

  • 2024

    Research grants (other domestic)

    New Frontiers for CAR T Cell Therapy in Breast Cancer
  • 2026

    Research grants (other domestic)

    Generating Early Phenotype CAR-T for Treatment of Osteosarcoma in Dogs

We acknowledge and pay respect to the Traditional Owners of the lands upon which our campuses are situated

Read about our commitment to reconciliation  

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia


View all Campus locations  
facebookIconlinkedinIconinstagramIcontwitterIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy  |  VaxFACTS

CRICOS number: 00116K     ABN: 84 002 705 224